General Overview: Unterschied zwischen den Versionen
| Zeile 45: | Zeile 45: | ||
! Activity !! Good Agricultural and Collection Practice (GACP) No GMP !! Part II of the EU GMP Guide † Reduced GMP !! Part I of the EU GMP Guide† Full GMP | ! Activity !! Good Agricultural and Collection Practice (GACP) No GMP !! Part II of the EU GMP Guide † Reduced GMP !! Part I of the EU GMP Guide† Full GMP | ||
|- | |- | ||
| − | | Cultivation, collection and harvesting of plants, algae, fungi and lichens, and collection of exudates || Cannabis (HC) Cannabis (EU) || | + | | Cultivation, collection and harvesting of plants, algae, fungi and lichens, and collection of exudates || Cannabis (HC) Cannabis (EU) || - || - |
|- | |- | ||
| Cutting, and drying of plants, algae, fungi, lichens and exudates * || Cannabis (HC) + GPP || Cannabis (EU) || Cannabis (EU) | | Cutting, and drying of plants, algae, fungi, lichens and exudates * || Cannabis (HC) + GPP || Cannabis (EU) || Cannabis (EU) | ||
Version vom 5. Juni 2020, 13:29 Uhr
Inhaltsverzeichnis
What is Cannabis for medical treatment?
Cultivation
For the cultivation of Cannabis the EU-GMPs have to be covered. Annex 7 Manufacture of Herbal Medicinal Products is a specific regulation for herbal medicines. More important is, that there are different regulatory opinions concerning cannabis flowers: Is it a drug a, finished drug product or an active pharmaceutical ingredient (API)?
In Germany there are local interpretations in place as drug or API. To get access to the EU you need a GMP certificate for drugs (this is the strongest regulation). With that you need to fulfill the EU-GMP-Guide Part 1 and Part 3 (were appropriate).
Basic treatments (Drying, Trimming)
Canada
Basic treatments like drying and trimming is a process that is from the Canadian view a non-GMP treatment. It has to follow the specific GPP regulations.
EU
Within the EU, drying and trimming is already a GMP-regulated process. There is only the differentiation as API or drug. The differences are not very significant in this phase. Anyway we need a pharmaceutical quality system with responsible management resources and adequat documentation of equipment and facility qualification, process validation and EU GMP certification.
USA
At present, the USA presents a very heterogeneous picture. The requirements in the various US states and their local regulations vary significantly. The priority is currently not to look at the USA, but will be discussed in detail in the future.
Distribution (Import)
Canada
Currently there is no content here.
EU
The import is regulated by the different member states. The reference in all member states is the EU GMP Guide and its Annex 1. It is the importer's responsibility to apply for a GMP certificate and thus trigger a GMP inspection of the supplier of cannabis products.
USA
Currently there is no content here.
Distribution (to Pharmacies)
Canada
Currently there is no content here.
EU
The distribution of drugs is regulated by the EU Guidelines on Good Distribution Practice (GDP) and the regulations in the member states. The EU GDP Guidelines are the general reference for all member states and is adopted by national laws and guidelines. It is the distributor's responsibility to comply with the national regulations for the distribution of medicinal cannabis products and the EU GDP Guidelines.
USA
Currently there is no content here.
Annex 7 of the EU GMP Guide and the impact on Cannabis products
The interpretation of the EU GMP Guide Annex 7 for Cannabis could help to understand the different appoach in Canada (Health Canada, HC) and the European Union (EU):
| Activity | Good Agricultural and Collection Practice (GACP) No GMP | Part II of the EU GMP Guide † Reduced GMP | Part I of the EU GMP Guide† Full GMP |
|---|---|---|---|
| Cultivation, collection and harvesting of plants, algae, fungi and lichens, and collection of exudates | Cannabis (HC) Cannabis (EU) | - | - |
| Cutting, and drying of plants, algae, fungi, lichens and exudates * | Cannabis (HC) + GPP | Cannabis (EU) | Cannabis (EU) |
| Expression from plants and distillation ** | Cannabis (HC) + GPP QAP | - | Cannabis (EU) |
| Comminution, processing of exudates, extraction from plants, fractionation, purification, concentration or fermentation of herbal substances | Cannabis (HC) + GPP + QAP | Beispiel | Cannabis (EU) |
| Further processing into a dosage form including packaging as a medicinal product | Beispiel | Beispiel | Cannabis (HC)
Cannabis (EU) |
† Explanatory Note. The GMP classification of the herbal material is dependent upon the use made of it by the manufacturing authorisation holder. The material may be classified as an active substance, an intermediate or a finished product. It is the responsibility of the manufacturer of the medicinal product to ensure that the appropriate GMP classification is applied.
- Manufacturers should ensure that these steps are carried out in accordance with the marketing authorisation/registration. For those initial steps that take place in the field, as justified in the marketing authorisation/registration, the standards of Good Agricultural and Collection Practice for starting materials of herbal origin (GACP) is applicable. GMP is applicable to further cutting and drying steps.
- Regarding the expression from plants and distillation, if it is necessary for these activities to be an integral part of harvesting to maintain the quality of the product within the approved specifications, it is acceptable that they are performed in the field, provided that the cultivation is in compliance with GACP. These circumstances should be regarded as exceptional and justified in the relevant marketing authorisation/ registration documentation. For activities carried out in the field, appropriate documentation, control, and validation according to the GMP principles should be assured. Regulatory authorities may carry out GMP inspections of these activities in order to assess compliance.
The GACPs are regulated by the WHO GACP Guideline.